These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32100811)

  • 1. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy.
    Wang Q; Zhu X; Wu Z; Sun T; Huang W; Wang Z; Ding X; Jiang C; Li F
    J Mater Chem B; 2020 Mar; 8(12):2410-2417. PubMed ID: 32100811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled drug release from polyelectrolyte-drug conjugate nanoparticles.
    Catarata R; Azim N; Bhattacharya S; Zhai L
    J Mater Chem B; 2020 Apr; 8(14):2887-2894. PubMed ID: 32191246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
    Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
    ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
    Yin N; Yu H; Zhang X; Lv X
    Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer.
    Dora CP; Kushwah V; Yadav V; Kuche K; Jain S
    Mol Pharm; 2024 Jun; 21(6):2699-2712. PubMed ID: 38747900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
    Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
    Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
    Han H; Wang J; Chen T; Yin L; Jin Q; Ji J
    J Colloid Interface Sci; 2017 Dec; 507():217-224. PubMed ID: 28800445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH and singlet oxygen dual-responsive GEM prodrug micelles for efficient combination therapy of chemotherapy and photodynamic therapy.
    Chen L; Zhuang W; Hu C; Yu T; Su X; Liang Z; Li G; Wang Y
    J Mater Chem B; 2020 Jul; 8(26):5645-5654. PubMed ID: 32538389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
    Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
    Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy.
    Qiu W; Zhang H; Chen X; Song L; Cui W; Ren S; Wang Y; Guo K; Li D; Chen R; Wang Z
    Nanomedicine (Lond); 2019 Sep; 14(17):2339-2353. PubMed ID: 31414945
    [No Abstract]   [Full Text] [Related]  

  • 15. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
    Karaca M; Dutta R; Ozsoy Y; Mahato RI
    Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
    Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
    Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
    Wang F; Zhang Z
    Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
    Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
    J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
    Yalcin TE; Ilbasmis-Tamer S; Takka S
    Int J Pharm; 2020 Apr; 580():119246. PubMed ID: 32205141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.